Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer Research Institute Names Six New Investigator Award Winners

06.08.2008
The Cancer Research Institute, a nonprofit charitable organization dedicated to advancing immunology to conquer cancer, announced that the Investigator Award Review Committee of the Institute’s Scientific Advisory Council, with the approval of the Institute’s Board of Trustees, has named six new investigators from its March 2008 application round, awarding $1.2 million in research funding.

The six scientists are conducting basic and tumor immunology laboratory investigations at distinguished academic institutions throughout the United States, as well as in Greece and Japan. Areas of research under investigation within the investigators’ laboratories include immune cell signaling pathways, immuno-modulation and regulatory mechanisms, and genetic factors of immune cell development and function.

The CRI Investigator Award Program aids scientists who are newly embarking on their independent academic research careers at the assistant professor level. These awards are not tied to any specific research project. Rather, the awards provide researchers the freedom to pursue promising lines of inquiry that their new responsibilities otherwise might not allow them to follow. The aim of the program is to provide flexibility and a degree of stability in what is essentially a make-or-break period in the scientist’s life. Since the Investigator Award Program’s inception in 1986, 120 investigators have received funding from the Cancer Research Institute, including the newest winners.

June 2008 Investigator Award Recipients

• Hongbo Chi, Ph.D., at St. Jude Children’s Research Hospital, Memphis, Tennessee, is investigating how the MAPK protein pathway, a pathway essential for integrating signals from antigen and cytokine receptors, functions in dendritic cell-mediated immune responses and stimulation of anti-tumor immunity. His study may be translated into new therapeutic strategies for treating cancers and autoimmune diseases.

• Morgan Huse, Ph.D., at the Memorial Sloan-Kettering Cancer Center, New York, New York, is studying how natural killer cells receive inhibitory and activating signals to induce natural killing responses to cancerous cells. Developing an understanding of natural killer cell mechanisms advances strategies to modulate their activity to better fight cancer.

• Hiroyoshi Nishikawa, M.D., Ph.D., at the University Graduate School of Medicine, Tsu, Mie, Japan, is clarifying questions of how regulatory T cells (Tregs) suppress immune responses by identifying which antigens are recognized by Tregs. This knowledge would provide an important next step to avoid undesired activation of Tregs by cancer vaccines aimed at inducing CD4+ Th helper cell-dependent development of antibodies.

• Neetu Gupta, Ph.D., at the Cleveland Clinic Foundation, Cleveland, Ohio, is enhancing the current understanding of B-cell activation, a process critical to antibody production. She is studying a protein called ezrin, which facilitates the B-cell response by participating in signal communication. Ultimately, this research promises a better comprehension of immunological diseases that result from interruption of signaling pathways and cellular architecture, and would enable identification of drug targets for specific and smarter therapy.

• Charalampos Spilianakis, Ph.D., at the Foundation of Research and Technology – Hellas (FORTH), Crete, Greece, is characterizing the protein complexes that generate and/or maintain interchromosomal interactions to understand how the genome is shaped and how the nuclear structure affects global gene expression. His research could lead to new insight into the link between the physical proximity of genomic loci and the increased probability of chromosomal translocations (mutations) and how these can lead to the creation of cancerous malignancies.

• Russell E. Vance, Ph.D., at the University of California, Berkeley, Berkeley, California, is addressing the fundamental question of how the immune system initially distinguishes normal from abnormal tissue by studying how a gene called Naip5 regulates the innate immune response. This understanding could help develop Naip5-related therapeutics that will stimulate innate immune responses against pathogenic intruders or tumors in cases when the immune system has inappropriately ignored these dangers.

More detailed descriptions of the investigators’ research can be viewed at http://www.cancerresearch.org/programs/research/investigator-award/investigators-2008-06.html. CRI extends its congratulations to each of this year’s award recipients. The next deadline for Investigator Award applications is March 1, 2009.

About the Cancer Research Institute
The Cancer Research Institute (CRI) is the world’s only non-profit organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes five Nobel Prize winners and thirty members of the National Academy of Sciences, CRI supports cutting-edge cancer research at top medical centers and universities throughout the world. The Cancer Research Institute is ushering in a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to cancer patients.

The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. This has consistently earned CRI an A grade or higher for fiscal disclosure and efficiency from the American Institute of Philanthropy and top marks from other charity watchdog organizations. http://www.cancerresearch.org

Brian Brewer | Newswise Science News
Further information:
http://www.cancerresearch.org

More articles from Awards Funding:

nachricht Yuan Chang and Patrick Moore win prize for the discovery of two cancer viruses
14.03.2017 | Goethe-Universität Frankfurt am Main

nachricht BMBF funding for diabetes research on pancreas chip
08.02.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>